IGM Biosciences, Inc. shares are experiencing an uptick following the initiation of coverage by BMO Capital Markets. On December 6, 2024, BMO Capital Markets issued a research note to investors, assigning an "outperform" rating to IGM Biosciences and setting a price target of $21.00. This target suggests a potential upside of approximately 122% from the current stock price, indicating strong confidence in the company's future performance. This positive outlook from BMO Capital Markets comes amid a mixed consensus from other analysts, with some maintaining a "hold" rating and others recommending a "buy."
The current price of IGM Biosciences shares is $9.76, reflecting a 3.16% increase from the previous close of $9.46.